Want to see IN:INDSWFTLAB full AI Analyst Report?
Top Page
Ind-Swift Laboratories Ltd.
(INDSWFTLAB)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹416.00
▲(83.26% Upside)
Action:Reiterated
Date:08/27/26
The score is held back primarily by deteriorating cash flow (multi-year negative operating and free cash flow) and recent revenue contraction/earnings volatility. These risks are only partly offset by a meaningfully improved balance sheet and a strong upward technical trend, while the high P/E valuation limits upside confidence.
Positive Factors
API manufacturing platform
The API and pharmaceutical-intermediate model places the company within an essential upstream role in medicine production. Serving both domestic and export markets provides a broad demand base, while regulatory-compliant manufacturing can support recurring customer relationships over the medium term.
Negative Factors
Recent revenue contraction
Two consecutive years of revenue contraction indicate weakened operating momentum rather than a single isolated fluctuation. Sustained lower sales can reduce capacity utilization, pressure product realizations, and make it harder to absorb fixed manufacturing and compliance costs.
Read all positive and negative factors
Positive Factors
Negative Factors
API manufacturing platform
The API and pharmaceutical-intermediate model places the company within an essential upstream role in medicine production. Serving both domestic and export markets provides a broad demand base, while regulatory-compliant manufacturing can support recurring customer relationships over the medium term.
Read all positive factors
Ind-Swift Laboratories Ltd. (INDSWFTLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹35.97B
Dividend Yield1.14%
Average Volume (3M)66.84K
Price to Earnings (P/E)57.0
Beta (1Y)0.88
Revenue Growth113.34%
EPS Growth-80.12%
CountryIN
Employees1,388
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)6.82
Shares Outstanding86,961,555
10 Day Avg. Volume68,179
30 Day Avg. Volume66,843
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.79
Price to Sales (P/S)1.71
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ind-Swift Laboratories Ltd. Business Overview & Revenue Model
Company Description
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, includ...
How the Company Makes Money
The company primarily makes money by producing and selling active pharmaceutical ingredients (APIs) and pharmaceutical intermediates to other pharmaceutical companies that use these inputs to manufacture finished formulations (tablets, capsules, i...
Ind-Swift Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Mar 2026 | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.65B | 6.41B | 5.62B | 12.81B | 12.07B | 10.39B |
| Gross Profit | 2.44B | 1.90B | 2.74B | 4.13B | 4.40B | 4.10B |
| EBITDA | 772.79M | 450.97M | 2.85B | 7.82B | 2.36B | 2.35B |
| Net Income | 573.25M | 414.15M | 2.50B | 4.21B | 475.97M | -21.49M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 16.73B | 14.38B | 14.60B | 18.24B | 18.01B |
| Cash, Cash Equivalents and Short-Term Investments | 4.42B | 4.72B | 4.82B | 4.94B | 231.54M | 333.68M |
| Total Debt | 0.00 | 205.01M | 408.41M | 166.22M | 8.62B | 9.53B |
| Total Liabilities | -13.84B | 2.89B | 2.65B | 6.48B | 11.42B | 12.00B |
| Stockholders Equity | 13.84B | 13.84B | 11.73B | 9.36B | 6.82B | 6.01B |
Cash Flow | ||||||
| Free Cash Flow | -472.94M | -1.08B | -898.80M | -2.08B | 1.82B | 1.32B |
| Operating Cash Flow | -202.50M | -198.64M | -254.74M | -1.63B | 1.95B | 1.50B |
| Investing Cash Flow | -1.04B | -1.28B | -1.10B | -1.23B | -133.68M | 47.72M |
| Financing Cash Flow | 961.18M | 1.47B | 692.05M | 6.99B | -1.86B | -1.41B |
Ind-Swift Laboratories Ltd. Technical Analysis
Positive
227.00
Price Trends
324.31
Positive
251.49
Positive
187.51
Positive
Market Momentum
20.98
Positive
56.19
Neutral
69.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Positive. The current price of 227 is below the 20-day moving average (MA) of 385.03, below the 50-day MA of 324.31, and above the 200-day MA of 187.51, indicating a bullish trend. The MACD of 20.98 indicates Positive momentum. The RSI at 56.19 is Neutral, neither overbought nor oversold. The STOCH value of 69.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INDSWFTLAB.
Ind-Swift Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹11.74B | 12.16 | ― | 0.31% | 10.20% | 11.70% | |
74 Outperform | ₹22.87B | 20.67 | ― | 0.56% | 20.87% | 116.29% | |
56 Neutral | ₹26.89B | -79.52 | ― | 0.28% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹35.97B | 57.00 | ― | 1.14% | 113.34% | -80.12% | |
51 Neutral | ₹36.04B | -1,295.36 | ― | 0.45% | 15.49% | -112.78% | |
47 Neutral | ₹24.83B | 902.31 | ― | 0.08% | 12.08% | ― |
* General Sector Average
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
386.50
289.46
298.29%
IN:HIKAL
Hikal Limited
217.80
-36.53
-14.36%
IN:INDOCO
Indoco Remedies Limited
263.10
-28.45
-9.76%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
585.25
53.41
10.04%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
724.90
118.25
19.49%
IN:VENUSREM
Venus Remedies Limited
1,796.40
1,344.91
297.88%
Ind-Swift Laboratories Ltd. Corporate Events
Ind-Swift Laboratories schedules virtual investor meet with Arihant Capital
Sep 23, 2026
Ind-Swift Laboratories Ltd. has scheduled a virtual group meeting with Arihant Capital on September 29, 2026, as part of its ongoing engagement with analysts and institutional investors under SEBI’s listing obligations framework. The company...
Ind-Swift Laboratories Publishes Notices for 31st AGM and Annual Report Access
Sep 6, 2026
Ind-Swift Laboratories Ltd., a listed Indian pharmaceutical company, manufactures and markets healthcare and drug products for a range of domestic and international customers. The company’s shares trade on BSE and NSE, positioning it within ...
Ind-Swift Laboratories Sets Q1 FY27 Earnings Call for August 17
Aug 12, 2026
Ind-Swift Laboratories Ltd. has scheduled an earnings conference call to discuss its financial results for the quarter ended June 30, 2026. The call will be held on Monday, August 17, 2026, at 3:00 p.m. IST and will feature senior finance and corp...
Ind-Swift Labs Revises EGM Notice on Preferential Issue for Expansion
Jul 29, 2026
Ind-Swift Laboratories Ltd. has issued a corrigendum to its July 10, 2026 notice convening an Extraordinary General Meeting on August 5, 2026, to update shareholders on changes to Item 1 regarding a proposed preferential issue. The EGM will be hel...
Ind-Swift Laboratories to Hold Extraordinary General Meeting via Video Conference on August 5
Jul 13, 2026
Ind-Swift Laboratories Ltd. has informed shareholders that it will hold its Extraordinary General Meeting on August 5, 2026, at 11:30 a.m. IST via video conferencing and other audio-visual means, with no physical venue. The company has published t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.